Who are Oral Capecitabine with Irinotecan's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/oral-capecitabine-with-irinotecan.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Oral Capecitabine with Irinotecan — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Oral Capecitabine with Irinotecan (Oral Capecitabine with Irinotecan) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimetabolite and topoisomerase I inhibitor combination. Area: Oncology.

phase 3 Antimetabolite and topoisomerase I inhibitor combination Thymidylate synthase (via 5-FU); Topoisomerase I Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Oral Capecitabine with Irinotecan (Oral Capecitabine with Irinotecan) — Pfizer. Capecitabine is converted to 5-fluorouracil to inhibit thymidylate synthase and disrupt DNA synthesis, while irinotecan inhibits topoisomerase I to prevent DNA unwinding during replication, together producing synergistic cytotoxic effects against cancer cells.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Oral Capecitabine with Irinotecan TARGET	Oral Capecitabine with Irinotecan	Pfizer	phase 3	Antimetabolite and topoisomerase I inhibitor combination	Thymidylate synthase (via 5-FU); Topoisomerase I

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimetabolite and topoisomerase I inhibitor combination class)

Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Oral Capecitabine with Irinotecan — Competitive Intelligence Brief. https://druglandscape.com/ci/oral-capecitabine-with-irinotecan. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab